Full-Time
Sales Lead
Hepatology Business Unit
Mirum Pharmaceuticals
201-500 employees
ASBT inhibitors for rare liver diseases
No salary listed
Remote in Germany
Remote
Up to 70% overnight travel is required.
Master's
 Sales & Account Management (1) |
|---|
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
- A Master's degree in science is required.
- At least 10 years of pharmaceutical or biotechnology experience, including at least 5 years of field experience.
- Demonstrated experience shaping launch, growth, or market-development strategies in complex healthcare environments.
- Strong understanding of the German healthcare system, academic centers, specialist networks, and regional access dynamics.
- Strong key opinion leader engagement and scientific fluency in complex, science-driven specialty markets.
- Ability to thrive in a fast-paced, dynamic, and collaborative environment.
- Ability to travel frequently, including up to 70% overnight travel, and hold a valid driver's license.
- Ability to combine strategic thinking with hands-on field execution, clear prioritization, and disciplined follow-through.
- High emotional intelligence, facilitation skills, and stakeholder influence across peers, leadership, and cross-functional groups.
- Ability to understand and communicate scientific information effectively within role, scope, and compliance boundaries.
- Build and lead the Hepatology sales team of Regional Account Managers across key German geographies.
- Develop and execute commercial plans for current hepatology priorities and support market development for future opportunities in rare liver diseases.
- Prioritize relevant specialist networks, regional opportunities, and key accounts to support effective field execution.
- Translate market and field insights into actionable strategies that support launch readiness, post-launch execution, and clear commercial priorities.
- Build structure in emerging market environments by setting direction, establishing priorities, and adapting strategy as new information becomes available.
- Support disease awareness and patient identification in rare liver diseases with high unmet need.
- Partner with specialist centers, key opinion leaders, and relevant institutions to support appropriate diagnosis, referral, and treatment pathways.
- Support the field team in identifying local implementation needs and opportunities to improve patient pathways.
- Ensure strategic engagement across expert centers, key stakeholders, and relevant regional health-system networks.
- Coach Regional Account Managers to develop account plans that reflect local stakeholder needs, care pathways, and execution priorities.
- Represent the field perspective in cross-functional planning with Medical Affairs, Market Access, and Marketing to shape aligned execution.
- Support accounts in navigating complex and evolving care environments.
- Recruit, develop, and coach a high-impact team of Regional Account Managers through structured field coaching, feedback, workshops, and best-practice exchange.
- Set clear expectations aligned with approved commercial and medical objectives and coach the team to make proactive, compliant decisions in dynamic field environments.
- Foster a culture of accountability, agility, shared ownership, and mission-driven execution.
- Lead directly and through influence, creating alignment across Regional Account Managers, cross-functional partners, and commercial leadership.
- Establish consistent field execution standards while encouraging local ownership and entrepreneurial problem-solving.
- Serve as the field leadership voice in commercial planning and execution, aligning stakeholders around evolving priorities while ensuring compliant field activities.
- Partner with Medical Affairs on scientific exchange and key opinion leader engagement.
- Partner with Marketing on brand strategy, field needs, and key tactics.
- Partner with commercial leadership on business planning and execution.
- Proven experience in rare disease and/or specialty care, ideally including hepatology or highly specialized care environments.
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2018
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 net product sales reached $176.2 million, lifting 2026 guidance to $680-$700 million.
- Volixibat's VISTAS met its primary endpoint, and FDA granted Breakthrough Therapy in PSC.
- Zilurgisertib received FDA Priority Review, offering a near-term launch in FOP after approval.
What critics are saying
- FDA recommended another Phase 3 for volixibat on August 5, 2026, delaying PSC filing.
- Mirum's Q1 2026 net loss hit $790.2 million after Bluejay's $726.3 million IPR&D charge.
- Zilurgisertib's September 26, 2026 PDUFA creates binary launch risk and post-approval execution pressure.
What makes Mirum Pharmaceuticals unique
- Mirum dominates rare pediatric cholestasis with LIVMARLI approvals in ALGS and PFIC.
- Its 2026 portfolio spans pediatric cholestasis, PSC, PBC, HDV, and FOP.
- The Bluejay acquisition added brelovitug, strengthening Mirum's rare-liver franchise beyond IBAT inhibition.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.
Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.
Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.
Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.
Mirum prices $600m convertible notes offering due 2032